Tigermed Expands Clinical Trial Capabilities With Oracle Health Sciences InForm

Chinese Clinical Research Organization Expands Deployment, Joins Oracle CRO Advantage Program to Grow Business in Local and Global Markets

(firmenpresse) - REDWOOD SHORES, CA -- (Marketwire) -- 01/08/13 -- Oracle (NASDAQ: ORCL)



, a leading clinical contract research organization (CRO) in China, recently selected to more efficiently develop, conduct and manage electronic data capture (EDC)-based clinical trials on behalf of its clients.

Being an existing user of Oracle Clinical for their paper trials, Tigermed selected Oracle Health Sciences InForm to extend its competitive edge in the local market and support international expansion with a trusted and highly scalable, leading clinical data management platform.

With its standardized feature sets, comprehensive data capture functionality and multi-language capabilities, Oracle Health Sciences InForm provides Tigermed with a robust solution to meet the needs of China's clinical trial sponsors -- while allowing for seamless expansion into the global marketplace.

Oracle Health Sciences InForm's comprehensive data review capabilities will enable Tigermed to gain better control over its data and generate efficiency and productivity gains in data management and remote monitoring.

Using Oracle Health Sciences InForm, Tigermed will be able to develop flexible source verification strategies that allow rapid changes to the source verification workload based on data quality.

In addition, Tigermed will be able to take advantage of Oracle Health Sciences Central Designer's centralized study design environment to accelerate trial development and increase trial efficiency.

To differentiate its business and gain a competitive advantage, Tigermed joined the Oracle CRO Advantage Program -- a program that provides a framework for driving CRO success with Oracle Health Sciences products through training, sales and marketing support and tools and regular communications on Oracle products and strategy.



"By adopting Oracle Health Sciences InForm, we will be positioned to support the growing number of clinical trials conducted in China, and their sponsors, with leading clinical data management capabilities," said Wen Chen, vice president, Tigermed. "Further, with Oracle's training and support through the Oracle CRO Advantage Program, we can maximize our investment in Oracle Health Sciences solutions -- securing the confidence of a growing number of clinical trial sponsors."

"With a heavy focus on growth, Tigermed requires a solution that will extend its clinical data management and EDC capabilities," said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences. "Tigermed relies on Oracle Health Sciences' world-class solutions, including Oracle Health Sciences InForm and Oracle Health Sciences Central Designer, to enable rapid trial set up, data accuracy, clinical trial productivity and informed decision making -- helping Tigermed to gain the trust of both local and global trial sponsors."

















Oracle engineers hardware and software to work together in the cloud and in your data center. For more information about Oracle (NASDAQ: ORCL), visit .

Oracle industry solutions leverage the company's best-in-class portfolio of products to address complex business processes relevant to health sciences, helping speed time to market, reduce costs, and gain a competitive edge.

Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Hangzhou Tigermed Consulting Co., Ltd is a leading full service clinical stage Contract Research Organization (CRO) in China. For more information about Tigermed (ChiNext 300347), visit



Greg Lunsford
Oracle
+1.650.506.6523


Mary Tobin
O'Keeffe & Company
+1.503.658.7396

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 08.01.2013 - 13:00 Uhr
Sprache: Deutsch
News-ID 217425
Anzahl Zeichen: 0

contact information:
Town:

REDWOOD SHORES, CA

Kategorie:

Software

Diese Pressemitteilung wurde bisher 259 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Tigermed Expands Clinical Trial Capabilities With Oracle Health Sciences InForm"
steht unter der journalistisch-redaktionellen Verantwortung von

Oracle Corporation (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Oracle Statement ...

REDWOOD SHORES, CA -- (Marketwired) -- 06/30/16 --"Five years ago, Oracle made a software development announcement which accurately reflected the future of the Itanium microprocessor. Two trials have now demonstrated clearly that the Itanium chi ...

Oracle Cloud Improves Financial Process Visibility and Cuts Upgrade Costs for Un ...

REDWOOD SHORES, CA -- (Marketwired) -- 06/30/16 -- has paired its top-notch educational programs with the technology to advance them. With , KU will drive strategic student educational initiatives, focus on operational efficiencies and reduce costs ...

Oracle Prices $14 Billion Aggregate Principal Amount of Investment Grade Notes ...

REDWOOD SHORES, CA -- (Marketwired) -- 06/29/16 -- Oracle Corporation (NYSE: ORCL) announced the pricing of its sale of $4,250,000,000 of 1.900% Notes due 2021 (the "2021 Notes"), $2,500,000,000 of 2.400% Notes due 2023 (the "2023 Not ...

Alle Meldungen von Oracle Corporation